The abnormal over-expression of c-Myc has been reported in human cancers such as breast, colon, and cervix carcinomas, as well as small-cell lung cancer, glioblastomas, osteosarcomas, and myeloid leukemia.11 The promoter region located 142–115 bp upstream from the P1 promoter of the c-Myc gene is composed of seven (NHEs), of which, NHE III1 controls 80–90% transcription of c-Myc gene and is responsible for mediating multiple pathways important in tumor cell survival. The gene discussed is MYC; the disease is cervical carcinoma.